Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics

Reliable methods for predicting functional consequences of variants in disease genes would be beneficial in the clinical setting. This study was undertaken to predict, and confirm in vitro, splicing aberrations associated with mismatch repair (MMR) variants identified in familial colon cancer patients. Six programs were used to predict the effect of 13 MLH1 and 6 MSH2 gene variants on pre‐mRNA splicing. mRNA from cycloheximide‐treated lymphoblastoid cell lines of variant carriers was screened for splicing aberrations. Tumors of variant carriers were tested for microsatellite instability and MMR protein expression. Variant segregation in families was assessed using Bayes factor causality analysis. Amino acid alterations were examined for evolutionary conservation and physicochemical properties. Splicing aberrations were detected for 10 variants, including a frameshift as a minor cDNA product, and altered ratio of known alternate splice products. Loss of splice sites was well predicted by splice‐site prediction programs SpliceSiteFinder (90%) and NNSPLICE (90%), but consequence of splice site loss was less accurately predicted. No aberrations correlated with ESE predictions for the nine exonic variants studied. Seven of eight missense variants had normal splicing (88%), but only one was a substitution considered neutral from evolutionary/physicochemical analysis. Combined with information from tumor and segregation analysis, and literature review, 16 of 19 variants were considered clinically relevant. Bioinformatic tools for prediction of splicing aberrations need improvement before use without supporting studies to assess variant pathogenicity. Classification of mismatch repair gene variants is assisted by a comprehensive approach that includes in vitro, tumor pathology, clinical, and evolutionary conservation data. Hum Mutat 0, 1–14, 2009. © 2009 Wiley‐Liss, Inc.

[1]  F. Couch,et al.  Prediction and assessment of splicing alterations: implications for clinical testing , 2008, Human mutation.

[2]  Alun Thomas,et al.  Classification of rare missense substitutions, using risk surfaces, with genetic‐ and molecular‐epidemiology applications , 2008, Human mutation.

[3]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[4]  Stephen B Gruber,et al.  Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms–mismatch repair (MAPP‐MMR) , 2008, Human mutation.

[5]  Sue Healey,et al.  Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. de Wind,et al.  Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes , 2007, Human mutation.

[7]  Michael O Woods,et al.  A new variant database for mismatch repair genes associated with Lynch syndrome , 2007, Human mutation.

[8]  C. Ishioka,et al.  Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. , 2007, Cancer research.

[9]  M. Trivett,et al.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer , 2007, Familial Cancer.

[10]  G. Guanti,et al.  In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects , 2006, BMC Genomics.

[11]  G. Giles,et al.  Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Iain M. Wallace,et al.  M-Coffee: combining multiple sequence alignment methods with T-Coffee , 2006, Nucleic acids research.

[13]  J. Hopper,et al.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. , 2006, Cancer research.

[14]  Qing Wang,et al.  Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing , 2006, Human mutation.

[15]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[16]  J. Hopper,et al.  The Colorectal Cancer Family Registry: An international resource for studying the genetic and molecular epidemiology of colorectal cancer , 2006 .

[17]  J. Stockman.  Conversion Analysis for Mutation Detection in MLH1 and MSH2 in Patients With Colorectal Cancer , 2006 .

[18]  Georgia Chenevix-Trench,et al.  Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms , 2005, Breast Cancer Research.

[19]  John L Hopper,et al.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Eero Pukkala,et al.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. , 2005, Gastroenterology.

[21]  H C van Houwelingen,et al.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment , 2005, Journal of Medical Genetics.

[22]  W. Foulkes,et al.  Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family , 2005, Journal of Medical Genetics.

[23]  A. Drousiotou,et al.  Gene symbol: GLB1. Disease: GM1 gangliosidosis infantile. , 2005, Human Genetics.

[24]  M. Kohonen-Corish,et al.  Gene symbol: MLH1. Disease: Hereditary nonpolyposis colorectal cancer. , 2005, Human Genetics.

[25]  A. Krainer,et al.  Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1 , 2004, Human mutation.

[26]  K. Schulmann,et al.  Familial adenomatous polyposis: Aberrant splicing due to missense or silent mutations in the APC gene , 2004, Human mutation.

[27]  C. Amos,et al.  Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs). , 2004, Mutation research.

[28]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[29]  M. Benito,et al.  Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. , 2004, Oncology reports.

[30]  A. Sharp,et al.  RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1 , 2004, Human mutation.

[31]  Yan Shen,et al.  Mutation analysis of five candidate genes in Chinese patients with hypospadias , 2004, European Journal of Human Genetics.

[32]  Ye Xu,et al.  Gene symbol: hMLH1. Disease: Hereditary nonpolyposis colorectal cancer. , 2004, Human Genetics.

[33]  Douglas F Easton,et al.  A full-likelihood method for the evaluation of causality of sequence variants from family data. , 2003, American journal of human genetics.

[34]  Jurg Ott,et al.  Distribution and characterization of regulatory elements in the human genome. , 2002, Genome research.

[35]  G. Capellá,et al.  Mismatch repair gene analysis in Catalonian families with colorectal cancer , 2002, Journal of medical genetics.

[36]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[37]  S. Henikoff,et al.  Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.

[38]  C. Cruz,et al.  Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing , 2002, Gut.

[39]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Davoodi-Semiromi,et al.  Aberrant RNA splicing in the hMSH2 gene: molecular identification of three aberrant RNA in Scottish patients with colorectal cancer in the West of Scotland. , 2000, American journal of medical genetics.

[41]  J. Saurin,et al.  Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer , 1999, Human Genetics.

[42]  A. Lindblom,et al.  Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours , 1999, British Journal of Cancer.

[43]  T. Kunkel,et al.  Mutator phenotypes of yeast strains heterozygous for mutations in the MSH2 gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Viel,et al.  Lack of PMS2 gene-truncating mutations in patients with hereditary colorectal cancer. , 1998, International journal of oncology.

[45]  J. Jass.  Diagnosis of hereditary non‐polyposis colorectal cancer , 1998, Histopathology.

[46]  T. Smyrk,et al.  Molecular Genetics and Clinical-Pathology Features of Hereditary Nonpolyposis Colorectal Carcinoma (Lynch Syndrome) , 1998, Oncology.

[47]  T. Smyrk,et al.  Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from pedigree anecdote to molecular genetic confirmation. , 1998, Oncology.

[48]  P. Møller,et al.  Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. , 1997, American journal of human genetics.

[49]  P. Propping,et al.  Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline mutations in hMSH2 or hMLH1 genes. , 1997, Human mutation.

[50]  Sajeev P. Cherian,et al.  In vitro transcription/translation assay for the screening of hMLH1 and hMSH2 mutations in familial colon cancer. , 1995, Gastroenterology.